An interventional study of carpal arch space augmentation (CASA) and standard of care (SOC) in Carpal Tunnel Syndrome, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by University of Arizona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Carpal Tunnel Syndrome with a site in United States — 10 open to participants now, 12 under way, none of them phase 3. Carpal Tunnel Syndrome · United States.
Among the 97 studies in Carpal Tunnel Syndrome with a site in United States, this one is the 17th largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2024, is one of 47 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 89th registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →10 of the 97 studies in Carpal Tunnel Syndrome with a site in United States are open now. Recruiting first, the newest first:
New York Institute of Technology · Sites in United States
Ages 18+
University of Nevada, Las Vegas · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Extremity Medical · Sites in United States
Ages 18–85
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 2 · Phase 4 10
First in 1997; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is above the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 50 across the 72 interventional studies, 107 across the 24 observational. Of the 68 that completed or were terminated, 16 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 97 have an industry lead sponsor. The 10 most frequent:
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
University of Arizona has 1 study filed under Carpal Tunnel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Carpal Tunnel Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04804293Mayo ClinicAssessment of Carpal Tunnel Syndrome by Shearwave Elastography | 2026-12-20 |
| NCT07158892University of Texas at AustinUnderstanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test | 2027-01-20 |
| NCT06907849University of Tennessee Graduate School of Medicine124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome | 2027-03 |
| NCT04206215Spaulding Rehabilitation HospitalNoninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome | 2027-07-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 97 studies in Carpal Tunnel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research proposes to evaluate the effectiveness of a novel device designed for the treatment of carpal tunnel syndrome. The device applies a small cyclic force to the wrist. The cycles include a small time period of force is applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep. The efficacy of the treatment is evaluated based on patient reported outcomes. Treatment efficacy will also be evaluated based on comparisons to patient reported outcomes for a SOC treatment.
Carpal tunnel syndrome is a commonly diagnosed disorder of the hand that affects 3.7% of the population. Carpal tunnel release surgery can provide some symptomatic relief to patients but surgical transection of the transverse carpal ligament can disrupt essential anatomical, biomechanical, and physiological functions of the carpal tunnel. This clinical trial seeks to determine the effectiveness of the CASA device in alleviating CTS pain by augmenting the carpal arch space. During an early investigation of the transverse carpal ligament, investigators discovered the biomechanical mechanism of carpal arch space augmentation (CASA) for median nerve decompression. The CASA approach is supported extensively through research findings utilizing geometric modeling, finite element analysis, in vitro cadaveric experiments, and in vivo human studies.
In this proposed pilot clinical trial, investigators will compare the device's performance with a widely accepted standard of care (SOC) brace intervention (Thermoformable Exos# Wrist Brace, DJO, Vista, CA). Incorporating the CASA intervention as part of a brace is an innovative intervention study design offering a unique opportunity to identify the additive benefit of CASA and for patients to benefit from the combined effects of both CASA and a SOC.
This study is designed to be a randomized, single-blinded, two-arm trial. A sufficient number of patients will be recruited such that a total of 76 subjects will successfully complete the baseline run-in period and be randomized, with consideration of a 20% attrition rate among randomized patients, to yield 60 participants with complete data. The CASA group will be required to undergo wrist compression during the evening. The wrist compression is achieved by automated inflation of the balloon for a saturated pressure of 140 mmHg, which is calibrated to impart the targeted therapeutic compression force on the patient's wrist of 10 N. The intervention period will last for four weeks for the CASA group. For the SOC group, there is no compression force, as it is measuring a brace-alone condition, and will similarly last for a period of four weeks.
Patients will self-administer their assigned intervention of either CASA or sham device, and will have off-site access to study materials and questionnaire journals, thus reducing participant burden and eliminating travel expense. Data forms are designed to capture all data elements with the structure to facilitate completeness, quality, and statistical analysis. Furthermore, exploratory endpoints will be evaluated such as (a) number of participants that began to take analgesics during the study intervention phase, (b) the number of participants who opted for surgery during the intervention and post-intervention follow-up phases, (c) per-protocol comparisons of treatment arms, and (d) the impact of sex on response to treatment.
The trial will consist of 3 phases for participants; run-in, intervention, follow-up. During the run-in phase, subjects will be randomized and undergo compliance testing, along with a brief duration of device wearing, to ensure they conform with protocol instructions.
Once participants successfully complete the run-in, they will move into the intervention phase. During the intervention phase, subjects will wear their arm's respective device/brace nightly. Participants will report their adherence each day before falling asleep and once again upon waking. Participants will receive weekly phone calls in which they will report the outcome measures for the week to a member of the study team who will record the data.
After the intervention phase, participants will proceed to the follow-up phase which will last for four weeks. In this phase, participants will continue to receive weekly phone calls.
Regardless what the participant's compliance to protocol requirements for abstaining from analgesics or wearing the device 8 hours per day, the participant will be asked to complete their journals per protocol for the primary intent to treat outcome. The data gained from these patients will be used in an exploratory statistical analysis to determine if any significant differences exist between patients who were compliant to the study and those who were not. If adherence standards are not consistently met within either treatment group, a sensitivity analysis using a per-protocol cohort will be performed. A significance level of 0.05 will be assumed for tests of the primary outcome. Analyses of secondary outcomes will be interpreted cautiously due to multiple comparisons.
It is predicted that an intervention period of wearing the CASA device will significantly improve patient reported outcomes of the primary endpoint, BCTQ SSS, and some of the secondary endpoints. Furthermore, it is expected that the positive effects of the CASA device intervention will continue after the treatment period has concluded. In both long-term wear and combined CASA-brace effect, it is anticipated that the CASA device group will outperform the SOC group in alleviating patient symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
History of musculoskeletal or neurological conditions that may confound Carpal Tunnel Syndrome symptoms, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm that will be given the test intervention device.
Device: carpal arch space augmentation (CASA)
Arm that is given a standard brace used for treating Carpal Tunnel Syndrome pain.
Device: standard of care (SOC)
A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
A BOA brace that can be adjusted to the arm of the participant.
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS)
The BCTQ SSS is a validated, self-reported instrument used in the assessment of pain intensity for patients with carpal tunnel syndrome. Higher numbers are worse outcomes. Possible scores range from 1 ("normal", "no pain", or "without difficulty") to 5 ("very serious", "continued", "more than 5 times") Change = (Baseline score - week 8 score)
Time frame: Baseline and up to 8 weeks
Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ FSS)
The BCTQ FSS is a validated, self-reported instrument used in the assessment of hand function for patients with carpal tunnel syndrome. Higher numbers are worse outcomes. Possible scores range from 1 (no difficulty) to 5 (cannot perform activity at all due to symptoms) Change = (Baseline score - week 8 score)
Time frame: Baseline and up to 8 weeks
Michigan Hand Outcomes Questionnaire (MHQ)
The MHQ is a valid and reliable instrument for the outcomes in comparing pain and task completion between right and left hands. For scales in sections I and II of the MHQ, higher numbers are worse outcomes. Possible scores range from 1 ("very good", "not at all difficult") to 5 ("very poor", very difficult") For scales in sections III and IV of the MHQ, higher numbers are better outcomes. Possible scores range from 1 (always) to 5 (never). For scales in sections V and VI of the MHQ, higher numbers are worse outcomes. Possible scores range from 1 (strongly agree) to 5 (strongly disagree) Change = (Baseline score - week 8 score)
Time frame: Baseline and up to 8 weeks
Visual Analog Scales for pain, tingling, and numbness
Scales used to report pain, tingling, numbness intensity by the participant. Higher numbers are worse outcomes. Possible scores range from 0 (no pain) to 10 (worst pain). Change = (Baseline score - week 8 score)
Time frame: Baseline and up to 8 weeks
Plan to share: No — No current plan exists. If data is shared in the future, it will only be deidentified data.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Jul 2026, 27 months after the start.
Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 27 months is above that.
Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.